177Lu-AB-3PRGD2Integrin α v β 3Targeted radionuclide therapyFirst-in-human studyPharmacokineticsDosimetrySafetyAdvanced tumorsIntegrin α v β 3 is overexpressed in various tumor cells and angiogenesis. To date, no drug has been proven to target it for therapy. A first-in-human study was ...
ClinicalTrials数据库提供临床试验177Lu-AB-3PRGD2 in Patients With Integrin αVβ3 Positive Tumors的登记号NCT05013086,试验分期Early Phase 1以及申办者Peking Union Medical College Hospital的信息,更过关于临床试验的其他信息查询就在戊戌数据美国临床试验数据库.